Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roman Perez

Showing results (61-70 of 134) with videos related to

Pageof 14
Sort By:
Biomaterials|December 6, 2016
Promoting angiogenesis with mesoporous microcarriers through a synergistic action of delivered silicon ion and VEGFKhandmaa Dashnyam, Guang-Zhen Jin, Joong-Hyun Kim, et al.
Cancers|May 8, 2020
Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical PracticeAditi P Singh, Elaine Shum, Lakshmi Rajdev, et al.
Current Cancer Drug Targets|April 1, 2016
Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter RegionYuanxin Liang, Jinwu Zeng, Linda Jelicks, et al.
ACS Medicinal Chemistry Letters|February 21, 2015
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cellsLars Ulrik Nordstrøm, Juan Sironi, Evelyn Aranda, et al.
Journal of Analytical Toxicology|January 13, 2016
Comparison of LC-MS-MS and GC-MS Analysis of Benzodiazepine Compounds Included in the Drug Demand Reduction Urinalysis ProgramErick Roman Perez, Joshua A Knapp, Carl K Horn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2005
Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell linesQun Dai, Yi-He Ling, Marie Lia, et al.
Psycho-Oncology|August 17, 2016
Speaking the same language: a feasibility trial for a novel visual communication tool for oncologist-patient treatment discussionsCristian P Zanartu, Fernando J Camacho, Nicole S Nevadunski, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2009
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)Tianhong Li, Liawaty Ho, Bilal Piperdi, et al.
International Journal of Radiation Oncology, Biology, Physics|January 10, 2017
<sup>18</sup>F-Fluorodeoxyglucose/Positron Emission Tomography Predicts Patterns of Failure After Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung CancerNitin Ohri, William R Bodner, Balazs Halmos, et al.
Plos One|July 29, 2016
Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung CancerJin S Im, Amanda C Herrmann, Chantale Bernatchez, et al.
Pageof 14

Showing results (61-70 of 134) with videos related to

Sort By:
Pageof 14
Biomaterials|December 6, 2016
Promoting angiogenesis with mesoporous microcarriers through a synergistic action of delivered silicon ion and VEGFKhandmaa Dashnyam, Guang-Zhen Jin, Joong-Hyun Kim, et al.
Cancers|May 8, 2020
Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical PracticeAditi P Singh, Elaine Shum, Lakshmi Rajdev, et al.
Current Cancer Drug Targets|April 1, 2016
Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter RegionYuanxin Liang, Jinwu Zeng, Linda Jelicks, et al.
ACS Medicinal Chemistry Letters|February 21, 2015
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cellsLars Ulrik Nordstrøm, Juan Sironi, Evelyn Aranda, et al.
Journal of Analytical Toxicology|January 13, 2016
Comparison of LC-MS-MS and GC-MS Analysis of Benzodiazepine Compounds Included in the Drug Demand Reduction Urinalysis ProgramErick Roman Perez, Joshua A Knapp, Carl K Horn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2005
Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell linesQun Dai, Yi-He Ling, Marie Lia, et al.
Psycho-Oncology|August 17, 2016
Speaking the same language: a feasibility trial for a novel visual communication tool for oncologist-patient treatment discussionsCristian P Zanartu, Fernando J Camacho, Nicole S Nevadunski, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2009
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)Tianhong Li, Liawaty Ho, Bilal Piperdi, et al.
International Journal of Radiation Oncology, Biology, Physics|January 10, 2017
<sup>18</sup>F-Fluorodeoxyglucose/Positron Emission Tomography Predicts Patterns of Failure After Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung CancerNitin Ohri, William R Bodner, Balazs Halmos, et al.
Plos One|July 29, 2016
Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung CancerJin S Im, Amanda C Herrmann, Chantale Bernatchez, et al.
Pageof 14